Kyzific 40mg Tablet contains Asciminib, a targeted therapy indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors (TKIs). Asciminib functions as a selective allosteric inhibitor of the BCR-ABL1 fusion protein, which plays a critical role in the pathogenesis of CML by promoting uncontrolled cell proliferation. By binding to the myristoyl pocket of the BCR-ABL1 protein, Asciminib inhibits its kinase activity, thereby reducing leukemic cell growth and proliferation. Kyzific is administered orally, with a recommended dosage tailored according to the patient’s clinical response and tolerance. Common adverse effects may include fatigue, nausea, musculoskeletal pain, and elevated liver enzymes, necessitating regular monitoring of hepatic function and blood counts during therapy. Kyzific should be used under strict medical supervision, with dose adjustments considered in cases of toxicity or drug interactions. It represents a valuable therapeutic option for patients with resistant or intolerant Ph+ CML, offering improved disease control and potential for durable remission. Physicians should evaluate the risk-benefit profile prior to initiation and counsel patients regarding adherence and potential side effects.